STEP-PROMOTE

  • Research type

    Research Study

  • Full title

    ImPRoving OutcoMes in individuals at clinical high risk fOr psychosis using cannabidiol: a double-blind, randomised conTrollEd trial

  • IRAS ID

    1006894

  • Contact name

    Philip McGuire

  • Contact email

    bphilip.mcguire@psych.ox.ac.uk

  • Sponsor organisation

    Research Governance, Ethics and Assurance (RGEA), University of Oxford

  • Clinicaltrials.gov Identifier

    NCT07434973

  • Research summary

    The trial is a randomized, double-blind, placebo-controlled, multi-centre, international clinical trial. Individuals aged 12-35 years old meeting clinical high risk for psychosis (CHR-P) criteria will be recruited for the trial intervention component of the trial. Participants are randomised 1:1 to treatment with oral CBD 300mg (oral solution 100mg/ml) twice daily, or a matching placebo, for 104 weeks and followed by a two week titration period where their dose of medicine will be gradually reduced. By using a battery of clinical outcome assessments, the trial will be able to assess several biomarkers to predict clinical outcomes and response to treatment with CBD. Participants will be invited to provide blood samples, stool samples, cerebral spinal fluid samples (if aged 18 years or over) and complete neuroimaging assessments. Individuals who are not found to have mental illness as defined by DSM-5 criteria will be recruited to a healthy control group, to validate the biomarker component of the trial. Healthy control volunteers will not take part in the treatment part of the trial and will not take CBD or placebo.

    Aims:
    • To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
    • To confirm the safety of CBD in individuals at clinical high risk for psychosis (CHR-P).

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    25/WM/0208

  • Date of REC Opinion

    2 Dec 2025

  • REC opinion

    Further Information Favourable Opinion